SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-24-038517
Filing Date
2024-02-16
Accepted
2024-02-16 16:31:12
Documents
18
Period of Report
2023-12-07
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d620689d8ka.htm   iXBRL 8-K/A 28752
2 EX-23.1 d620689dex231.htm EX-23.1 2741
3 EX-99.1 d620689dex991.htm EX-99.1 74101
4 EX-99.2 d620689dex992.htm EX-99.2 52281
5 EX-99.3 d620689dex993.htm EX-99.3 59214
  Complete submission text file 0001193125-24-038517.txt   381100

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA vnda-20231207.xsd EX-101.SCH 2890
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20231207_lab.xml EX-101.LAB 18702
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20231207_pre.xml EX-101.PRE 11722
19 EXTRACTED XBRL INSTANCE DOCUMENT d620689d8ka_htm.xml XML 4615
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-34186 | Film No.: 24648890
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)